Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, fatal disorder with no effective treatment. We used simple genetic models of ALS to screen phenotypically for potential therapeutic compounds. We screened libraries of compounds in C. elegans, validated hits in zebrafish, and tested the most potent molecule in mice and in a small clinical trial. We identified a class of neuroleptics that restored motility in C. elegans and in zebrafish, and the most potent was pimozide, which blocked T-type Ca2+ channels in these simple models and stabilized neuromuscular transmission in zebrafish and enhanced it in mice. Finally, a short randomized controlled trial of sporadic ALS subjects demonstrated stabilization of motility and evidence of target engagement at the neuromuscular junction. Simple genetic models are, thus, useful in identifying promising compounds for the treatment of ALS, such as neuroleptics, which may stabilize neuromuscular transmission and prolong survival in this disease.

[1]  R. Robitaille,et al.  Opposite Synaptic Alterations at the Neuromuscular Junction in an ALS Mouse Model: When Motor Units Matter , 2017, The Journal of Neuroscience.

[2]  Denis C. Bauer,et al.  Genetic correlation between amyotrophic lateral sclerosis and schizophrenia , 2017, Nature Communications.

[3]  P. Drapeau,et al.  Simple animal models for amyotrophic lateral sclerosis drug discovery , 2016, Expert opinion on drug discovery.

[4]  Wei Zhou,et al.  The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation. , 2016, International journal of oncology.

[5]  M. Kiernan,et al.  Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[6]  Yasuto Itoyama,et al.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[7]  R. Baruchello,et al.  Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. , 2014, Bioorganic & medicinal chemistry letters.

[8]  P. Drapeau,et al.  Loss and gain of FUS function impair neuromuscular synaptic transmission in a genetic model of ALS. , 2013, Human molecular genetics.

[9]  P. Drapeau,et al.  Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo , 2013, Neurobiology of Disease.

[10]  P. Drapeau,et al.  Calcium Channel Agonists Protect against Neuromuscular Dysfunction in a Genetic Model of TDP-43 Mutation in ALS , 2013, The Journal of Neuroscience.

[11]  Barbara E. Shapiro,et al.  Electromyography and neuromuscular disorders : clinical-electrophysiologic correlations , 1997 .

[12]  P. Drapeau,et al.  Methylene Blue Protects against TDP-43 and FUS Neuronal Toxicity in C. elegans and D. rerio , 2012, PloS one.

[13]  M. Uchino,et al.  Significant CMAP decrement by repetitive nerve stimulation is more frequent in median than ulnar nerves of patients with amyotrophic lateral sclerosis , 2012, Muscle & nerve.

[14]  G. Rouleau,et al.  Mutant TDP-43 and FUS Cause Age-Dependent Paralysis and Neurodegeneration in C. elegans , 2012, PloS one.

[15]  R. N. Brogden,et al.  Pimozide: A Review of Its Pharmacological Properties and Therapeutic Uses in Psychiatry , 2012, Drugs.

[16]  A. Eisen,et al.  The split hand syndrome in amyotrophic lateral sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  M. Glicksman.  The preclinical discovery of amyotrophic lateral sclerosis drugs , 2011, Expert opinion on drug discovery.

[18]  J. Julien,et al.  Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. , 2011, Brain : a journal of neurology.

[19]  Y. Daali,et al.  Two structurally different T‐type Ca2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats , 2011, Fundamental & clinical pharmacology.

[20]  E. Brustein,et al.  FUS and TARDBP but Not SOD1 Interact in Genetic Models of Amyotrophic Lateral Sclerosis , 2011, PLoS genetics.

[21]  E. Melamed,et al.  The “Dying-Back” Phenomenon of Motor Neurons in ALS , 2011, Journal of Molecular Neuroscience.

[22]  T. Gillingwater,et al.  Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy , 2010, Neuropathology and applied neurobiology.

[23]  R. Bowser,et al.  Transgenic Rat Model of Neurodegeneration Caused by Mutation in the TDP Gene , 2010, PLoS genetics.

[24]  G. Rouleau,et al.  Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. , 2010, Human molecular genetics.

[25]  D. Rubinsztein,et al.  Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases , 2010, The Journal of Biological Chemistry.

[26]  Jeffrey A. Cohen,et al.  Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis? , 2007, Medical hypotheses.

[27]  Timothy R Mahoney,et al.  Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarb-sensitivity assay , 2006, Nature Protocols.

[28]  Pico Caroni,et al.  Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF , 2006, Nature Neuroscience.

[29]  J. Glass,et al.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man , 2004, Experimental Neurology.

[30]  R. Lewis,et al.  Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. , 2002, Human gene therapy.

[31]  T. Snutch,et al.  Differential Inhibition of T-Type Calcium Channels by Neuroleptics , 2002, The Journal of Neuroscience.

[32]  P. Drapeau,et al.  Synaptic drive to motoneurons during fictive swimming in the developing zebrafish. , 2001, Journal of neurophysiology.

[33]  P. Caroni,et al.  Early and Selective Loss of Neuromuscular Synapse Subtypes with Low Sprouting Competence in Motoneuron Diseases , 2000, The Journal of Neuroscience.

[34]  M. Mohajeri,et al.  Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. , 1999, Human gene therapy.

[35]  P. Leigh,et al.  A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis , 1998, Neurology.

[36]  A. Słowik,et al.  [Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes]. , 1998, Neurologia i neurochirurgia polska.

[37]  W. Robberecht,et al.  A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. , 1998, Neurology.

[38]  G. Parry,et al.  A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis , 1996 .

[39]  R. Barohn,et al.  A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. , 1996, Annals of neurology.

[40]  C. Kimmel,et al.  Stages of embryonic development of the zebrafish , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[41]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[42]  S. Appel,et al.  Decremental motor responses to repetitive nerve stimulation in ALS , 1994, Muscle & nerve.

[43]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[44]  D. Richman,et al.  Neuromuscular transmission in amyotrophic lateral sclerosis , 1993, Muscle & nerve.

[45]  B. Mlinar,et al.  Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. , 1992, Molecular pharmacology.

[46]  S. Sheu,et al.  Antipsychotic pimozide is a potent Ca2+ channel blocker in heart. , 1990, Molecular pharmacology.

[47]  A. Shapiro,et al.  Pimozide treatment of tic and Tourette disorders. , 1987, Pediatrics.

[48]  D. W. Mulder,et al.  Myasthenic syndrome in patients with amyotrophic lateral sclerosis , 1959, Neurology.

[49]  R. Hodes.  Electromyographic study of defects of neuromuscular transmission in human poliomyelitis. , 1948, Archives of neurology and psychiatry.